M&A Deal Summary

Axol Acquires Phenocell

On October 21, 2024, Axol acquired life science company Phenocell

Acquisition Highlights
  • This is Axol’s 2nd transaction in the Life Science sector.
  • This is Axol’s 1st transaction in France.

M&A Deal Summary
Date 2024-10-21
Target Phenocell
Sector Life Science
Buyer(s) Axol
Deal Type Add-on Acquisition

Target

Phenocell

Grasse, France
Phenocell is a research-based R&D company that designs phenotypic assays for research and drug discovery using iPSC-derived cell lines to its existing neuroscience, pain and touch, and cardiovascular products and services. Phenocell is based in Grasse, France.

Search 199,442 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Axol

Easter Bush, United Kingdom
Category Company
Founded 2013
Sector Life Science
DESCRIPTION

Axol supplies high-quality human cells especially live human neurons created by stem cell technology, too many of the world’s biggest and best-known pharma companies and research institutions, to be used for medical research, disease modelling, and drug development. Axol was founded in 2013 and is based in Easter Bush, United Kingdom.

DEAL STATS #
Overall 2 of 2
Sector (Life Science) 2 of 2
Type (Add-on Acquisition) 1 of 1
Country (France) 1 of 1
Year (2024) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2021-03-17 Censo

Roslin, United Kingdom

Censo is a cell biology CRO with focused expertise in iPSC-related technologies. The company creates relevant, customizable human neurological and inflammatory disease models with induced pluripotent stem cells (iPSC). With deep expertise in neuroscience, immunology, stem cell biology, and gene editing, Censo Biotechnologies specializes in model and assay design for drug discovery. Censo has the ability to select or engineer the desired human genetic background by creating iPSC from patient samples or using CRISPR for gene editing. It has established robust, propriety differentiation protocols for sensory and excitatory cortical neurons, astrocytes, microglia, macrophages, monocytes, and dendritic cells as well as co-cultures. Censo was formed in 2016 and is based in Roslin, United Kingdom.

Buy -
Mergr

Product

Company

Legal